American College of Cardiology Meeting In Brief: Antidepressant therapy post-MI
Executive Summary
Antidepressant therapy post-MI: In 81 myocardial infarction survivors, the SSRI paroxetine (SmithKline Beecham's Paxil) and the tricyclic nortryptiline (Sandoz' Pamelor and generics) were equally effective in treating clinical depression, although nortryptiline was associated with more adverse events, Mitchell Finkel, MD, University of Pittsburgh, reported March 26. Two of 41 paroxetine patients discontinued therapy due to AEs, one of which was cardiac related, compared to eight of 40 nortryptiline patients, seven of which were cardiac related. Nortryptiline was associated with increases in heart rate and QTc intervals, while paroxetine was not associated with any significant changes in heart rate, blood pressure or pro-arrhythmic events...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth